Company

Rubedo Life Sciences, Inc

Rubedo Life Sciences develops small molecule drugs targeting senescent cells.

About

Founded in 2018 and based in California, US, Rubedo Life Sciences develops drugs to target and eliminate senescent cells. Its lead candidate, RLS-1496, is a topical treatment for skin lesions. In April 2024, the company raised USD 40 million in Series A funding co-led by Ahren Innovation Capital, Khosla Ventures, Hevolution Foundation, R42, and Modi Ventures.

2Funding rounds

9Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in